<DOC>
	<DOCNO>NCT00216034</DOCNO>
	<brief_summary>A randomize control study conduct patient resect gastric cancer assign postoperative adjuvant therapy TS-1 alone PSK combine TS-1 , objective examine validate outcome , QOL prognostic factor ( host tumor factor ) , explore factor enhance antitumor effect TS-1 .</brief_summary>
	<brief_title>Randomized Controlled Study Postoperative Adjuvant Therapy Gastric Cancer Using TS-1 TS-1+PSK</brief_title>
	<detailed_description>The 5-year survival gastric cancer surgery remain poor cancer advance stag II , IIIA , IIIB IV . Tegafur-gimeracil-oteracil potassium ( TS-1 ) use first line treatment advance recurrent gastric cancer . But TS-1 accompany adverse drug reaction bone marrow suppression readily see conventional oral fluoropyrimidines . Among randomized control trial postoperative adjuvant chemotherapy gastric cancer , beneficial result survival rate use Krestin ( PSK ) combination chemotherapy report . With objective enhance antitumor effect TS-1 improve QOL patient , plan validate clinical significance combine PSK TS-1 therapy postoperative adjuvant therapy gastric cancer , use principle TS-1 regimen 2-week dose 1-week 6 month follow 2-week dose 2-week 6 month .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<mesh_term>Krestin</mesh_term>
	<criteria>Patients microscopic stage II IIIA resectable gastric cancer Patients receive preoperative cancer therapy ( radiotherapy , chemotherapy immunotherapy ) Patients serum immunosuppressive acidic protein ( IAP ) measure within 2 week surgery Patients metachronous synchronous multiple cancer Patients without severe impairment renal , hepatic bone marrow function Patients judge capable tolerating surgery Patients preoperative performance status 0 2 Patients serious concurrent complication ( bone marrow suppression , diarrhea infection ) Patients judge capable tolerating treatment , give write informed consent participate study Patients fresh hemorrhage gastrointestinal tract Patients retention body fluid necessitating treatment Patients infection , intestinal palsy intestinal occlusion Patients pregnant hope become pregnant study period Patients diabetes treat continuous use insulin show poor glycemic control Patients history ischemic heart disease Patients concurrent psychiatric disease psychotic symptom , judge difficulty participate study Patients receive continuous administration steroid Patients experience serious drug allergy past Others , patient judge investigator subinvestigator inappropriate subject</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Gastric Cancer</keyword>
	<keyword>TS-1</keyword>
	<keyword>PSK</keyword>
	<keyword>Disease-free survival</keyword>
	<keyword>Overall survival</keyword>
</DOC>